alisertib
alisertib: developed by 1 company · 5 clinical trials tracked.
alisertib evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could alisertib → PBYI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) Small Cell Lung Cancer ( SCLC ); Hormone Receptor Positive H… | Phase 2 |
Clinical Trials (5)
A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
Primary endpoint: Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events)
A Phase 2 Study of Alisertib in Combination With Endocrine Therapy in Patients With HR+, HER2-negative Recurrent or Metastatic Breast Cancer
Primary endpoint: Objective Response Rate (ORR) Within Dose Subgroup
A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Primary endpoint: Objective response rate (ORR) within biomarker-defined subgroup
A Phase I/Ib Study of Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Primary endpoint: Determination of Maximum Tolerated Dose (MTD) (Cohort A)
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Primary endpoint: Tumor Response Rate Defined as 100% Times the Number of Patients Who Meet the Criteria for Complete Response (CR) or Partial Response (PR) Using RECIST Criteria Version 1.1
Frequently asked questions
Who is developing alisertib?
alisertib is being developed by PUMA BIOTECHNOLOGY, INC..
How many clinical trials involve alisertib?
BioSniper tracks 5 clinical trials involving alisertib.